The Latest Cardiac and Vascular News
Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction. SAN FRANCISCO, May 19, 2021 /PRNewswire/ — The clinical study was designed to evaluate […]
WASHINGTON, May 20, 2021 /PRNewswire/ — MCRA, LLC, a leading medical device and biologics advisory firm and clinical research organization (CRO) integrating US and International Regulatory, Clinical Research, Reimbursement, Healthcare Compliance, and Quality Assurance, is pleased to announce the hiring of Fernando Aguel as Vice President, Heart Failure & Circulatory Support Regulatory Affairs. Fernando […]
Proven CFO with extensive financial leadership and commercialization experience, including multiple publicly listed life sciences companies DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Dale Sander as Chief Financial […]
Concord, NC, May 20, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Hydromer, Inc. (the “Company”) (HYDI:OTC) is proud to announce it has been selected as the key coatings and services partner for Avinger, Inc.’s intravascular image-guided, catheter-based systems for diagnosis and treatment of patients with Peripheral Artery Disease (PAD). Avinger’s best-in class product […]
MCT is added to the list of cardiac monitoring capabilities on a single platform including physiological parameter monitoring SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital monitoring biosensor technology, announced today it has launched its VitalPatch RTM mobile cardiac telemetry (MCT) solution. The launch of the MCT […]
–Xenter Continues Rapid Expansion to Advance Device/Data/Drug Technologies for Interventional Medicine, Pharmaceutical Advancements and Digital Health– SALT LAKE CITY–(BUSINESS WIRE)–On the heels of last week’s announcement of the closing of its $12M Series A offering, Xenter, Inc. (XenterMD.com), the world’s first start-up Device-Data-Drug healthcare technologies company, today announced the appointment of Scott […]
At 1 year, outcomes similar to overall cohort of patients IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement (TAVR) and […]
– Treatment with sotatercept in the ongoing SPECTRA Phase 2 trial was associated with improvements in resting and exercise hemodynamics at week 24 – – Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH and in other diseases – – Company-hosted investor and analyst conference […]
Data Support Continued Development of Single-course Gene Editing Therapies for Treatment of Cardiovascular Disease, Led by VERVE-101 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the publication of proof-of-concept data highlighting the company’s gene […]
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced new data demonstrating the accuracy of the HeartFlow Planner in providing modeled post-percutaneous coronary intervention (PCI) fractional flow reserve derived from computed tomography (FFRct) values, which are an important measure for understanding the effectiveness of a PCI […]
